Obesity - Novo Nordisk
As leaders within the science of obesity, we are working to make obesity a healthcare priority, defeat stigma and support better access to evidence-based care. Scientific and medical experts are increasingly recognising obesity as a serious chronic disease.
News Details - novonordisk.com
3 days ago · Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence. Bagsværd, Denmark, 17 January 2025 – Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial ...
Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7
3 days ago · Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence Novo Nordisk A/S Fri, Jan 17, 2025, 4:11 AM 5 min read
The Science Behind Obesity | Novo Nordisk U.S.
As leaders in the science of obesity, we are working to make obesity a healthcare priority, defeat stigma and support better access to evidence-based care. We aim to be the leading force in the science behind obesity. Learn more about our ambitious R&D pipeline.
Novo Nordisk says its obesity drug in higher dose shows 20.7
3 days ago · Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the weight loss achieved with Eli Lilly's rival ...
Novo Nordisk high dose weight loss data ‘a double edged …
3 days ago · After Novo Nordisk reported results from its Phase 3b STEP UP trial, which showed that adults with obesity achieved a 20.7% weight loss over 72 weeks with once-weekly 7.2 mg semaglutide and ...
Obesity | Novo Nordisk U.S.
US24OB00216 May 2024. View a full list of Novo Nordisk's current chronic weight management products along with prescribing information and links to their individual product websites.
Transformational Prevention Unit - Novo Nordisk
As leaders within the science of obesity, Novo Nordisk established the Transformational Prevention Unit (TPU) to tackle one of the world’s foremost health challenges and drive change within obesity prevention.
Driving Change in Obesity | Novo Nordisk U.S.
At Novo Nordisk, we are dedicated to making obesity a healthcare priority. We are committed to helping improve the lives of people with obesity by changing how the world sees, prevents and treats obesity.
Obesity is recognized as a chronic disease and a significant threat to public health by national organizations such as AACE, ACE, and AMA. 1-3 Obesity is often classified by a body mass index (BMI) of 30 kg/m 2 or higher. 3